162 related articles for article (PubMed ID: 25771209)
1. Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Grégoire L; Smith T; Senanayake V; Mochizuki A; Miville-Godbout E; Goodenowe D; Di Paolo T
Behav Brain Res; 2015 Jun; 286():328-37. PubMed ID: 25771209
[TBL] [Abstract][Full Text] [Related]
2. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
Bourque M; Grégoire L; Di Paolo T
Behav Brain Res; 2018 Jan; 337():183-185. PubMed ID: 28917506
[TBL] [Abstract][Full Text] [Related]
3. Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease.
Wood PL; Smith T; Lane N; Khan MA; Ehrmantraut G; Goodenowe DB
Lipids Health Dis; 2011 Dec; 10():227. PubMed ID: 22142382
[TBL] [Abstract][Full Text] [Related]
4. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
5. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
6. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
7. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Samadi P; Grégoire L; Rouillard C; Bédard PJ; Di Paolo T; Lévesque D
Ann Neurol; 2006 Feb; 59(2):282-8. PubMed ID: 16437566
[TBL] [Abstract][Full Text] [Related]
8. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
9. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
Grégoire L; Morin N; Ouattara B; Gasparini F; Bilbe G; Johns D; Vranesic I; Sahasranaman S; Gomez-Mancilla B; Di Paolo T
Parkinsonism Relat Disord; 2011 May; 17(4):270-6. PubMed ID: 21315648
[TBL] [Abstract][Full Text] [Related]
10. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Koprich JB; Fox SH; Johnston TH; Goodman A; Le Bourdonnec B; Dolle RE; DeHaven RN; DeHaven-Hudkins DL; Little PJ; Brotchie JM
Mov Disord; 2011 Jun; 26(7):1225-33. PubMed ID: 21465551
[TBL] [Abstract][Full Text] [Related]
11. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Morissette M; Samadi P; Hadj Tahar A; Bélanger N; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):446-54. PubMed ID: 20026151
[TBL] [Abstract][Full Text] [Related]
12. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Grégoire L; Jourdain VA; Townsend M; Roach A; Di Paolo T
Parkinsonism Relat Disord; 2013 May; 19(5):508-14. PubMed ID: 23402994
[TBL] [Abstract][Full Text] [Related]
13. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():27-38. PubMed ID: 25046277
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor.
Nadeau J; Smith T; Lamontagne-Proulx J; Bourque M; Al Sweidi S; Jayasinghe D; Ritchie S; Di Paolo T; Soulet D
Brain Res; 2019 Dec; 1725():146460. PubMed ID: 31525350
[TBL] [Abstract][Full Text] [Related]
15. Plasmalogen precursor mitigates striatal dopamine loss in MPTP mice.
Miville-Godbout E; Bourque M; Morissette M; Al-Sweidi S; Smith T; Jayasinghe D; Ritchie S; Di Paolo T
Brain Res; 2017 Nov; 1674():70-76. PubMed ID: 28830769
[TBL] [Abstract][Full Text] [Related]
16. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
Morin N; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2010 Jun; 58(7):981-6. PubMed ID: 20074579
[TBL] [Abstract][Full Text] [Related]
17. Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain.
Riahi G; Morissette M; Lévesque D; Rouillard C; Samadi P; Parent M; Di Paolo T
Neurochem Int; 2012 Dec; 61(7):1160-71. PubMed ID: 22940695
[TBL] [Abstract][Full Text] [Related]
18. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
19. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
20. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
Grondin R; Hadj Tahar A; Doan VD; Ladure P; Bédard PJ
Naunyn Schmiedebergs Arch Pharmacol; 2000 Feb; 361(2):181-6. PubMed ID: 10685874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
